• Profile
Close

Relative contribution of basal and post-prandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide

Diabetes, Obesity and Metabolism Feb 18, 2019

Umpierrez G, et al. - Researchers analyzed the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on the relative contribution of basal hyperglycemia (BHG) and post-prandial hyperglycemia (PPHG) to overall hyperglycemia across HbA1c categories after six months of treatment intensification with dulaglutide 1.5 mg as monotherapy or with one or two oral drugs in type 2 diabetes patients. To measure the change in relative contributions of BHG and PPHG, they used data from five phase 3 studies (N=673). Investigators found that relative contributions of BHG increased and PPHG reduced with increasing HbA1c levels at baseline. Even as overall glycemia got better in every HbA1c category with decreasing values, this pattern was sustained at 6 months. According to findings, dulaglutide lowers HbA1c in patients with type 2 diabetes by lowering both basal and post-prandial hyperglycemia at different levels of HbA1c.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay